Gilead Sciences Inc.’s remdesivir had little or no effect on COVID-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization has found.
Posted in
#canadahealth #canadahealthy #canadalistings #canadastory #canadianhealth Health Search Canada Online Listing
Remdesivir has little effect on hospital stay or mortality in COVID-19 patients, WHO study finds
